Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms

In a note out today, Deutsche Bank reiterated a buy rating and $97 price target on Botox maker Allergan

, implying substantial upside from where the shares currently trade. The bank also reiterated a hold and $33 price target on Forest Labs

. Deutsche Bank also reiterated buy ratings on Teva

and Medicis Pharmaceutical

with price targets of $46 and $44, respectively.